Extensive evidence from three decades of research has established that diminished cerebral glucose metabolism (DCGM, also known as glucose hypometabolism) is a key underlying pathology in the Alzheimer’s brain.1 This leaves neurons less able to utilize glucose for fuel, leading to an energy shortage in the brain.1 DCGM occurs early in the disease and correlates with symptoms and disease progression.5-9
Axona helps address this deficiency by providing ketone bodies as an alternative fuel source for neurons.3,4 Axona is the only available prescription medical food that addresses DCGM.2,4 Adding Axona to Alzheimer’s disease management addresses different aspects of the disease at the same time and may further enhance memory and cognition.*4
Add Axona. Add what's been missing from Alzheimer's therapy.
Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease.
Diminished cerebral glucose metabolism in Alzheimer’s disease5,6
Find out more about one of the earliest brain changes that occurs in Alzheimer’s disease.
Ketone bodies: the brain’s natural back-up fuel1,4
Find out how Axona can help during times of DCGM.
Only Axona safely supplies effective levels of ketone bodies to target DCGM*2,4
Read Accera's response to the recent FDA warning letter.